Companies / BOC Sciences / Sutimlimab
BOC Sciences

Sutimlimab | BOC Sciences

Sutimlimab is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. Sutimlimab has been approved by US FDA for the treatment of adults with cold agglutinin disease (CAD).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.